Adverse events
| Grade 3-4 adverse events . | # (%) patients . |
|---|---|
| Hematologic | |
| Anemia | 1 (11) |
| Lymphopenia | 1 (11) |
| Thrombocytopenia | 1 (11) |
| Hemolysis | 1 (11) |
| Other | |
| Fever | 2 (22) |
| Vascular (hypertension) | 2 (22) |
| Gastrointestinal (elevated GGT, ALT or AST) | 3 (33) |
| Grade 3-4 adverse events . | # (%) patients . |
|---|---|
| Hematologic | |
| Anemia | 1 (11) |
| Lymphopenia | 1 (11) |
| Thrombocytopenia | 1 (11) |
| Hemolysis | 1 (11) |
| Other | |
| Fever | 2 (22) |
| Vascular (hypertension) | 2 (22) |
| Gastrointestinal (elevated GGT, ALT or AST) | 3 (33) |
All grade 3 and 4 adverse events based on CTCAE v4.0 that were possibly, probably, or definitely related to study therapy are listed, along with the number (and percentage) of patients who experienced each toxicity. All patients enrolled were assessed for adverse events.